News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Subscribe To Our Newsletter & Stay Updated
